Therapeutic Response

not BCR::ABL1 status confers therapeutic sensitivity to Dasatinib in patients with Acute Lymphoblastic Leukemia.

Statements

Source and description
Sprycel (dasatinib [anhydrous]) [product information]. EMA. The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy.
Sprycel (dasatinib [anhydrous]) [product information]. EMA. The European Medicines Agency (EMA) has authorized dasatinib (anhydrous) for the treatment of pediatric patients with newly diagnosed Philadelphia acute lymphoblastic leukemia (ALL) in combination with chemotherapy. The product information for this indication further states that his indication is based on a multicenter, historically-controlled phase 2 study that followed the chemotherapy regime detailed in another clinical trial, AIEOP-BFM ALL 2000 (chemotherapeutic standard multi-agent chemotherapy protocol).